2026 RNDS | TIMELY-PLEX Study @wearesrna
2026 RNDS | TIMELY-PLEX Study  @wearesrna
Uploaded October 2026 | Updated November 2026, 3 hours ago
In this session from the 2026 Rare Neuroimmune Disorders Symposium (RNDS), John J. Chen, MD, PhD, of Mayo Clinic, speaking remotely from Minnesota, described TIMELY-PLEX, a trial testing whether plasma exchange (PLEX) improves recovery after severe optic neuritis or myelitis [00:00:05]. He reviewed standard treatment with high-dose IV steroids, what PLEX involves, and why earlier studies of PLEX may look better than they are [00:01:10]. He explained the design: everyone receives steroids, and people are randomized to PLEX right away or to PLEX only if they have not recovered after 7 to 14 days, with almost 400 people at more than 30 US centers [00:05:52]. Dr. Chen covered who can join, including adults within 14 days of symptom onset, and the outcomes measured [00:07:57]. Michael Levy read questions on timing with steroids, MRI confirmation, telling a stroke from inflammation, and results by disease type [00:17:26].

John J. Chen, MD, PhD, is a neuro-ophthalmologist and Professor of Ophthalmology and Neurology at Mayo Clinic. He provides care for people with visual disorders related to neurological causes and works closely with neurology, rheumatology, and neurosurgery. Dr. Chen completed his MD and PhD at the University of Virginia and his ophthalmology residency and neuro-ophthalmology fellowship at the University of Iowa before joining Mayo Clinic in 2014. His clinical and research focus includes optic neuritis (MOG antibody disease (MOGAD), neuromyelitis optica spectrum disorder (NMOSD), and multiple sclerosis), idiopathic intracranial hypertension, and neuro-ophthalmic imaging. He serves as Neuro-Ophthalmology Fellowship Director and is co-lead investigator of the TIMELY-PLEX trial, a PCORI-funded multicenter clinical trial of plasma exchange for acute optic neuritis across more than 30 US sites. He is an Associate Editor for Ophthalmology and the Journal of Neuro-Ophthalmology and has published more than 300 peer-reviewed articles.

Dr. Chen serves as Vice President of the North American Neuro-Ophthalmology Society (NANOS) and previously served as President of the Minnesota Academy of Ophthalmology and Chair of the Upper Midwest Neuro-Ophthalmology Group. He is a member of the American Ophthalmological Society and the American Eye Study Club and serves as an Oral Board Examiner for the American Board of Ophthalmology. His awards include the AAO Senior Achievement Award, the Real World Ophthalmology Inspiring Academic Leader Award, four-time Mayo Clinic Ophthalmology Teacher of the Year leading to induction into the Educators Hall of Fame, and the Mayo Clinic Distinguished Educator Award.

00:00 Introduction to TIMELY-PLEX
01:10 Standard Treatment and PLEX
03:16 Why Earlier Studies Can Mislead
05:24 How the Trial Is Designed
07:57 Who Can Join
08:56 Vision and Spinal Cord Criteria
11:56 Masked Evaluators and Safety
12:54 Outcomes That Matter
14:02 How to Refer Someone
15:06 Take-Home Messages
17:26 Audience Questions
22:21 Results by Disease Type and Closing
2026 RNDS | TIMELY-PLEX Study2025 RNDS | Rehabilitation and recovery in rare neuroimmune disorders2026 RNDS | Getting Back to WorkThe Power Of Community: Teaser2025 RNDS | 2025 Update on the Q-cells Study1112. Social Determinants of Health in Rare Neuroimmune Disorders2026 RNDS | Sexual Dysfunction and Intimacy2024 RNDS | A Conversation: How Do I Identify a Relapse?1302. Pelvic Floor Therapy for Bladder and Bowel ManagementABCs of NMOSD 702. CAR-T in NMOSD2023 RNDS en Español | Programas educativos y de apoyo de SRNA1312. Parenting is Hard | Part 6
SRNA |

2026 RNDS | TIMELY-PLEX Study

SHARE TO X SHARE TO REDDIT SHARE TO FACEBOOK WALLPAPER